Phase 1 Evaluation of JNJ-88549968, a T-cell Redirecting Antibody, in Patients with CALR-mutated Myeloproliferative Neoplasms

The primary objective of this study is to evaluate the safety and tolerability of **JNJ-88549968**, a T-cell redirecting antibody, in patients with **CALR-mutated Myeloproliferative Neoplasms**. This is clinically relevant as it aims to determine the potential of JNJ-88549968 to provide a novel therapeutic approach for this specific genetic mutation in myeloproliferative neoplasms, which could lead to improved patient outcomes.

The clinical trial involves a total of **55 participants** diagnosed with **CALR-mutated Myeloproliferative Neoplasms**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion and exclusion criteria.

The clinical trial is a **Phase 1** study designed to evaluate the safety and efficacy of JNJ-88549968, a T-cell redirecting antibody, in patients with **CALR-mutated Myeloproliferative Neoplasms**. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the investigators know which treatment the participants are receiving, thereby minimizing bias. The estimated recruitment start date is March 13, 2024, with an anticipated end date of February 10, 2027, indicating a total trial duration of approximately three years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation, including medical history, physical examination, and laboratory tests. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess the treatment's safety and efficacy, and collect necessary data. The end-of-study visit will conclude the trial for each participant, involving final assessments and debriefing.

The expected length of participant involvement in the study is contingent upon the individual's response to the treatment and the overall study timeline. Participants may be withdrawn from the study early if they experience adverse effects, fail to comply with study procedures, or if the investigator deems it in the participant's best interest. The study is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the trial duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess the efficacy of the investigational product through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial assessment of the product's safety and potential efficacy. The estimated recruitment start date is March 13, 2024, with an anticipated end date of February 10, 2027. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the investigational product's impact on the targeted medical condition. The trial will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy assessments.